William Chou

Directeur Général chez PASSAGE BIO, INC.

Fortune : - $ au 30/04/2024

51 ans

Consumer Services

Health Technology

Postes actifs de William Chou

Sociétés	Poste	Début	Fin
PASSAGE BIO, INC.	Directeur/Membre du Conseil	10/10/2022	-
	Directeur Général	10/10/2022	-
	President	-	-

Sociétés	Poste	Début	Fin
Aruvant Sciences, Inc. Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY.	Directeur Général	19/11/2019	-

Yale School of Management	Masters Business Admin
University of Pittsburgh School of Medicine	Doctorate Degree
Princeton University	Undergraduate Degree

Internationale

Etats-Unis

Opérationnelle

Sectorielle

Consumer Services	4
Health Technology	3

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	1
PASSAGE BIO, INC.	Health Technology

Entreprise privées	1
Aruvant Sciences, Inc. Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY.	Health Technology

Entreprise privées

Health Technology